The company saw revenue grow 2.53 per cent over 2009 to NT$3.8bn thanks to growing demand for active pharmaceutical ingredients (APIs), particularly those for cancer drugs, from customers in a number of key international markets.CEO Jo Shen said: ???[ScinoPharm] has expanded export sales for over 13 products to international markets such as the United States, Canada, Europe and Japan, gaining inte